Morgan Stanley analyst Jeffrey Hung resumed coverage of Exelixis with an Equal Weight rating and $21 price target. The firm’s estimates for Cabometyx sales are inline with the consensus. The analyst is looking for additional details ahead of upcoming readouts like CONTACT-02 topline results in the second half of 2023 and COSMIC-313 data in 2023 in order to get more constructive on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>